

PATENT COOPERATION TREATY


PCT

REC'D 25 APR 2005

WIPO

PCT

INTERNATIONAL PRELIMINARY EXAMINATION REPORT
(PCT Article 36 and Rule 70)

Applicant's or agent's file reference PN02116-PCT		FOR FURTHER ACTION See Notification of Transmittal of International Preliminary Examination Report (Form PCT/IPEA/416)	
International application No. PCT/NO 03/00443	International filing date (day/month/year) 29.12.2003	Priority date (day/month/year) 30.12.2002	
International Patent Classification (IPC) or both national classification and IPC C07K2/00			
Applicant AMERSHAM HEALTH AS et al.			
<p>1. This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36.</p> <p>2. This REPORT consists of a total of 8 sheets, including this cover sheet.</p> <p><input checked="" type="checkbox"/> This report is also accompanied by ANNEXES, i.e. sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT).</p> <p>These annexes consist of a total of 4 sheets.</p>			
<p>3. This report contains indications relating to the following items:</p> <p>I <input checked="" type="checkbox"/> Basis of the opinion</p> <p>II <input type="checkbox"/> Priority</p> <p>III <input checked="" type="checkbox"/> Non-establishment of opinion with regard to novelty, inventive step and industrial applicability</p> <p>IV <input type="checkbox"/> Lack of unity of invention</p> <p>V <input checked="" type="checkbox"/> Reasoned statement under Rule 66.2(a)(ii) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement</p> <p>VI <input type="checkbox"/> Certain documents cited</p> <p>VII <input type="checkbox"/> Certain defects in the international application</p> <p>VIII <input type="checkbox"/> Certain observations on the international application</p>			
Date of submission of the demand 05.07.2004		Date of completion of this report 21.04.2005	
Name and mailing address of the international preliminary examining authority:  European Patent Office D-80298 Munich Tel. +49 89 2399 - 0 Tx: 523656 epmu d Fax: +49 89 2399 - 4465		Authorized Officer Jenn, T Telephone No. +49 89 2399-7348	



**INTERNATIONAL PRELIMINARY
EXAMINATION REPORT**

International application No. PCT/NO 03/00443

I. Basis of the report

1. With regard to the **elements** of the international application (*Replacement sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to this report since they do not contain amendments (Rules 70.16 and 70.17)*):

Description, Pages

1-3, 5-17 as published
4 filed with telefax on 04.04.2005

Sequence listings part of the description, Pages

1-3 as published

Claims, Numbers

1-11 filed with telefax on 04.04.2005

2. With regard to the **language**, all the elements marked above were available or furnished to this Authority in the language in which the international application was filed, unless otherwise indicated under this item.

These elements were available or furnished to this Authority in the following language: , which is:

- ☐ the language of a translation furnished for the purposes of the international search (under Rule 23.1(b)).
☐ the language of publication of the international application (under Rule 48.3(b)).
☐ the language of a translation furnished for the purposes of international preliminary examination (under Rule 55.2 and/or 55.3).

3. With regard to any **nucleotide and/or amino acid sequence** disclosed in the international application, the international preliminary examination was carried out on the basis of the sequence listing:

- ☒ contained in the international application in written form.
☒ filed together with the international application in computer readable form.
☐ furnished subsequently to this Authority in written form.
☐ furnished subsequently to this Authority in computer readable form.
☐ The statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.
☐ The statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished.

4. The amendments have resulted in the cancellation of:

- ☐ the description, pages:
☐ the claims, Nos.:
☐ the drawings, sheets:

**INTERNATIONAL PRELIMINARY
EXAMINATION REPORT**

International application No. **PCT/NO 03/00443**

5. ☐ This report has been established as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed (Rule 70.2(c)).
(Any replacement sheet containing such amendments must be referred to under item 1 and annexed to this report.)

6. Additional observations, if necessary:

III. Non-establishment of opinion with regard to novelty, inventive step and industrial applicability

1. The questions whether the claimed invention appears to be novel, to involve an inventive step (to be non-obvious), or to be industrially applicable have not been examined in respect of:
- ☐ the entire international application,
 - ☒ claims Nos. 11
because:
 - ☒ the said international application, or the said claims Nos. 11 relate to the following subject matter which does not require an international preliminary examination (specify):
see separate sheet
 - ☐ the description, claims or drawings (*indicate particular elements below*) or said claims Nos. are so unclear that no meaningful opinion could be formed (*specify*):
 - ☐ the claims, or said claims Nos. are so inadequately supported by the description that no meaningful opinion could be formed.
 - ☐ no international search report has been established for the said claims Nos.
2. A meaningful international preliminary examination cannot be carried out due to the failure of the nucleotide and/or amino acid sequence listing to comply with the standard provided for in Annex C of the Administrative Instructions:
- ☐ the written form has not been furnished or does not comply with the Standard.
 - ☐ the computer readable form has not been furnished or does not comply with the Standard.

V. Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

1. Statement

Novelty (N)	Yes: Claims	1-11
	No: Claims	
Inventive step (IS)	Yes: Claims	1-11
	No: Claims	
Industrial applicability (IA)	Yes: Claims	1-10
	No: Claims	

2. Citations and explanations

**INTERNATIONAL PRELIMINARY
EXAMINATION REPORT**

International application No. **PCT/NO 03/00443**

see separate sheet

Basis of the report

Re Item III

Non-establishment of opinion with regard to novelty, inventive step and industrial applicability

The method as claimed in **claim 11** relates to subject-matter considered by this Authority to be covered by the provisions of Rule 67.1(iv) PCT (diagnostic method carried out on the living human or animal body). Consequently, no opinion will be formulated on the industrial applicability of the subject-matter of this claim (Article 34(4)(a)(i) PCT, see also the PCT-guidelines IV-2.4.(d) and IV-2.5); an opinion on novelty and inventive step will be given for the alleged effects of a compound of claim 1 in the method of claim 11.

Re Item V

Reasoned statement with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

1 Claims 1-7 and 10-11:

- 1.1 The document **D4** is regarded as being the closest prior art to the subject-matter of claim 1, and discloses (the references in parentheses applying to this document) a compound for imaging and treatment of angiogenesis, which is of formula (I) $A-(B)_n-C$, wherein A is a chelator moiety capable of complexing a radionuclide metal or a moiety capable of binding to a halogen; B is a spacer group; C is an angiogenesis targeting molecule; and n is 0 or 1 (Abstract).
- 1.2 The subject-matter of claim 1 therefore **differs** from this known compound in that it comprises the amino acid sequence of formula (I) of the application.
- 1.3 The subject-matter of claim 1 can therefore be considered **new**.
- 1.4 The **problem** to be solved by the present invention may therefore be regarded as to provide alternative compounds for imaging.
- 1.5 The **solution** to this problem proposed in claim 1 of the present application is considered

as involving an **inventive** step (Article 33(3) PCT), because a compound of formula (III) is not suggested by the available prior art documents.

- 1.6 A pharmaceutical composition comprising the new and inventive compound of formula (III), and the use of said compound in a method of generating enhanced images of a human or animal body can also be considered new and inventive.
- 1.7 Therefore, the subject-matter of **claims 1-7, 10 and 11** complies with the requirements of Article 33(2) and 33(3) PCT.

2 Claims 8 and 9:

- 2.1 The document **D3** is regarded as being the closest prior art to the subject-matter of claims 8 or 9, and discloses a series of monomeric monocyclic peptide inhibitors and dimeric bicyclic peptide inhibitors based on exposed loop fragments of the growth factor VEGF-D, VEGF-C or VEGF, methods of making them as well as pharmaceutical compositions containing them and methods (for imaging) utilizing them (Abstract, claims 1, 48, 49, 66 and 69). None of said peptides comprises the amino acid sequence of formula (I) of the application.
- 2.2 The subject-matter of claims 8 and 9 therefore **differs** from this known compound in that it claims a peptide comprising the amino acid sequence of formula (II) or a peptide comprising the amino acid sequence SEQ ID No: 1-10 (all peptides comprising the amino acid sequence of formula (I) of the application).
- 2.3 The subject-matter of claims 8 and 9 can therefore be considered **new**.
- 2.4 The **problem** to be solved by the present invention may therefore be regarded as to provide alternative peptides for imaging.
- 2.5 The **solution** to this problem proposed in claims 8 and/or 9 of the present application is considered as involving an inventive step (Article 33(3) PCT), because a peptide comprising the amino acid sequence of formula (II) or a peptide comprising the amino acid sequence SEQ ID No: 1-10 are not suggested by the available prior art documents.


- 2.6 Therefore, the subject-matter of **claims 8 and 9** complies with the requirements of Article 33(2) and 33(3) PCT.
- 3 An agent of formula (III) according to claim 1 has an application for preparing a pharmaceutical composition; and a peptide according to claim 9 or 10 is comprised in an agent of formula (III). Therefore, the subject-matter of claims 1-10 complies with the requirements of Article 33(4) PCT.
- 4 **Certain observations on the international application**
- 4.1 The embodiments of the invention described on page 15 (the whole Example 2) do not fall within the scope of the claims (the peptide according to Example 2 is not of formula (I), as it comprises a Lys at the position for Z¹, and a Pro at the position for X⁶, which do not enter in the definition of Z¹ and X⁶ given in claim 1).
This inconsistency between the claims and the description leads to doubt concerning the matter for which protection is sought, thereby rendering the claims unclear (Article 6 PCT).
- 4.2 The features of claim 4 are not referred to in the description. Claim 4 is therefore not supported by the description as required by Article 6 PCT.
- 4.3 Attention is drawn to the following: The use of the expression "*incorporated by reference*" (page 6, line 8; page 8, line 3; and page 9, line 15) is not allowed in some designated Contracting States.
- 4.4 There is a spelling mistake in claim 5: "An agent as claimed in claim 5" for "An agent as claimed in claim 4".

Claims

1. A targetable therapeutically active and/or diagnostic agent of formula (III)



wherein the vector V is a peptide comprising the amino acid sequence of formula (I)



or formula (II)



wherein

X² is an amino acid selected from the group Val, Leu, Ile and Tyr

X³ is an amino acid selected from the group Arg, Lys, Tyr, Ile and Asn

X⁵ is an amino acid selected from the group Asp and Asn

X⁶ is an amino acid selected from the group Gly, Asn and Gln

X⁷ is an amino acid selected from the group Ala, Met, Gln, Arg, Glu and Val.

X⁸ is an amino acid selected from the group Pro, Gly, Ser and Arg

X⁹ is an amino acid selected from the group Ala, Met, Gln, Arg, Gly and Val

Z¹ represent an amino acid residue capable of forming a disulphide bond, preferably a cysteine or a homocysteine residue, or a residue capable of forming a thioether preferably the residue is Q-C(=O) wherein Q represents -(CH₂)_n or -(CH₂)_n-C₆H₄ where n represents a positive integer 1 to 10 or is absent and

Z² represent an amino acid residue capable of forming a disulphide bond, preferably a cysteine or a homocysteine residue or is absent

Y¹ represents 1-10 amino acids or is absent

L represents a bond, a spacer or a linker and

Z represents an antineoplastic agent, a reporter or a group that optionally can carry an imaging moiety M.

2. A targetable therapeutically active and/or diagnostic agent according to claim 1

wherein the vector V is a peptide comprising the amino acid sequence

Cys-Arg-Val-Arg-Ile-Asp-Gly-Ala-Pro-Ala-Cys, (SEQ ID NO 1),

Cys-Arg-Val-Arg-Ile-Asp-Asn-Met-Pro-Met-Cys, (SEQ ID NO 2),

Cys-Arg-Val-Arg-Ile-Asn-Gly-Gln-Pro-Gln-Cys, (SEQ ID NO 3),

Cys-Arg-Val-Lys-Ile-Asp-Gly-Arg-Pro-Met-Cys, (SEQ ID NO 4),

Cys-Arg-Leu-Lys-Ile-Asp-Gly-Met-Pro-Arg-Cys, (SEQ ID NO 5),


Cys-Arg-Ile-Lys-Ile-Asp-Gly-Glu-Gly-Gln-Cys, (SEQ ID NO 6),

Cys-Arg-Val-Tyr-Ile-Asp-Gly-Val-Ser-Val-Cys, (SEQ ID NO 7),

Cys-Arg-Val-Ile-Ile-Asp-Gly-Arg-Arg-Met-Cys, (SEQ ID NO 8),

Cys-Arg-Tyr-Asn-Ile-Asp-Gly-Arg-Pro-Gln-Cys, (SEQ ID NO 9) or
Cys-Arg-Ile-Arg-Ile-Asp-Gln-Arg-Pro-Ala-Cys, (SEQ ID NO 10).

3. An agent according to any of the previous claims 1 and 2 where Z is a chelating agent of formula IV



(IV)

where:

each R^1 , R^2 , R^3 and R^4 is independently an R group;

each R group is independently H or C_{1-10} alkyl, C_{3-10} alkylaryl, C_{2-10} alkoxyalkyl, C_{1-10} hydroxyalkyl, C_{1-10} alkylamine, C_{1-10} fluoroalkyl, or 2 or more R groups, together with the atoms to which they are attached form a carbocyclic, heterocyclic, saturated or unsaturated ring.

4. An agent as claimed in claim 1 in any of the previous claims 1 to 3 wherein Z comprises a reporter moiety M wherein the reporter moiety comprises metal radionuclides, paramagnetic metal ions, fluorescent metal ions, heavy metal ions or cluster ions.

5. An agent as claimed in claim 5 wherein the reporter moiety M comprises ^{90}Y , ^{88m}Tc , ^{111}In , ^{47}Sc , ^{67}Ga , ^{51}Cr , ^{177m}Sn , ^{67}Cu , ^{167}Tm , ^{87}Ru , ^{188}Re , ^{177}Lu , ^{189}Au , ^{203}Pb , ^{141}Ce or ^{18}F .

6. An agent as claimed in any of the previous claims 1 to 5 where each reporter (Z) can carry a multiplicity of vectors V.

7. An agent as claimed in claims 1 and 2 where the antineoplastic agent, Z represent cyclophosphamide, chloroambucil, busulphan, methotrexate, cytarabine, fluorouracil, vinblastine, paclitaxel, doxorubicin, daunorubicin, etoposide, teniposide, cisplatin, amsacrine or docetaxel.

04/04 2005 09:16 FAX +47 23186019

AMERSHAM HEALTH

→ EPO

010

20

8. A peptide comprising the amino acid sequence of formula (II)



wherein

X^7 is an amino acid selected from the group Ala, Met, Gln, Arg, Glu and Val,

X^8 is an amino acid selected from the group Ala, Met, Gln, Arg, Gly and Val

Z^1 represent an amino acid residue capable of forming a disulphide bond, preferably a cysteine or a homocysteine residue, or a residue capable of forming a thioether preferably the residue is $Q\text{-C(=O)}$ wherein Q represents $-(CH_2)_n$ or $-(CH_2)_n\text{-C}_6\text{H}_4$ where n represents a positive integer 1 to 10 or is absent and

Z^2 represent an amino acid residue capable of forming a disulphide bond, preferably a cysteine or a homocysteine residue or is absent

Y^1 represents 1-10 amino acids or is absent

or pharmaceutically acceptable salts thereof.

9. A peptide comprising the amino acid sequence

Cys-Arg-Val-Arg-Ile-Asp-Gly-Ala-Pro-Ala-Cys, (SEQ ID NO 1),

Cys-Arg-Val-Arg-Ile-Asp-Asn-Met-Pro-Met-Cys, (SEQ ID NO 2),

Cys-Arg-Val-Arg-Ile-Asn-Gly-Gln-Pro-Gln-Cys, (SEQ ID NO 3),

Cys-Arg-Val-Lys-Ile-Asp-Gly-Arg-Pro-Met-Cys, (SEQ ID NO 4),

Cys-Arg-Leu-Lys-Ile-Asp-Gly-Met-Pro-Arg-Cys, (SEQ ID NO 5),

Cys-Arg-Ile-Lys-Ile-Asp-Gly-Glu-Gly-Gln-Cys, (SEQ ID NO 6),

Cys-Arg-Val-Tyr-Ile-Asp-Gly-Val-Ser-Val-Cys, (SEQ ID NO 7),

Cys-Arg-Val-Ile-Ile-Asp-Gly-Arg-Arg-Met-Cys, (SEQ ID NO 8),

Cys-Arg-Tyr-Asn-Ile-Asp-Gly-Arg-Pro-Gln-Cys, (SEQ ID NO 9) or

Cys-Arg-Ile-Arg-Ile-Asp-Gln-Arg-Pro-Ala-Cys, (SEQ ID NO 10).

10. A pharmaceutical composition comprising an effective amount of a compound of general Formula (III) or a salt thereof, together with one or more pharmaceutically acceptable adjuvants, excipients or diluents.

11. A method of generating enhanced images of a human or animal body previously administered with a contrast agent composition comprising a compound as claimed in claims 1 to 6, which method comprises generating an image of at least part of said body.

04/04 2005 09:15 FAX +47 23186019

AMERSHAM HEALTH

→ EPO

003

4

Lys - Lysine
 Asn - Asparagine
 Gln - Glutamine
 Ala - Alanine
 Met - Methionine
 Glu - Glutamic acid

In a first aspect, the present invention provides a new peptide that targets VEGFR 2.

The new peptide comprising the amino acid sequence of formula (I)

$Z^1\text{-Arg-X}^2\text{-X}^3\text{-Ile-X}^4\text{-X}^5\text{-X}^7\text{-X}^8\text{-X}^9\text{-Z}^2\text{-Y}^1$ (Formula I)

wherein

X^2 is an amino acid selected from the group Val, Leu, Ile and Tyr

X^3 is an amino acid selected from the group Arg, Lys, Tyr, Ile and Asn

X^4 is an amino acid selected from the group Asp and Asn

X^5 is an amino acid selected from the group Gly, Asn and Gln

X^7 is an amino acid selected from the group Ala, Met, Gln, Arg, Glu and Val,

X^8 is an amino acid selected from the group Pro, Gly, Ser and Arg

X^9 is an amino acid selected from the group Ala, Met, Gln, Arg, Gly and Val

Z^1 represent an amino acid residue capable of forming a disulphide bond, preferably a cysteine or a homocysteine residue, or a residue capable of forming a thioether preferably the residue is Q-C(=O) wherein Q represents $-(\text{CH}_2)_n$ or $-(\text{CH}_2)_n\text{-C}_6\text{H}_4$ where n represents a positive integer 1 to 10 or is absent and

Z^2 represent an amino acid residue capable of forming a disulphide bond, preferably a cysteine or a homocysteine residue or is absent

Y^1 represents 1-10 amino acids or is absent

or pharmaceutically acceptable salts thereof.

More specific the new peptide comprises the amino acid sequence of formula (II)

$Z^1\text{-Arg-Val(Arg/Lys)Ile-Asp-Gly-X}^7\text{-Pro-X}^8\text{-Z}^2\text{-Y}^1$ Formula (II)

wherein

X^7 is an amino acid selected from the group Ala, Met, Gln, Arg, Glu and Val,

X^8 is an amino acid selected from the group Ala, Met, Gln, Arg, Gly and Val

Z^1 represent an amino acid residue capable of forming a disulphide bond, preferably a cysteine or a homocysteine residue, or a residue capable of forming a thioether preferably the residue is Q-C(=O) wherein Q represents $-(\text{CH}_2)_n$ or $-(\text{CH}_2)_n\text{-C}_6\text{H}_4$